Vaxcyte VAX-31 Vaccine Met Trial Endpoints
The investigational vaccine outperformed competitors in a trial covering 31 bacterial serotypes.
Updated on Oct. 5, 2026 in COVID-19
Live Poll
Do you believe newer medical vaccines are generally more effective than the options currently available?
Vaxcyte has reported that its VAX-31 vaccine met primary endpoints in a Phase 3 clinical trial involving 3,500 adults aged 50 and older. The vaccine showed potential to protect against a broader range of bacterial strains than current market options.
Why it matters
The development signals a potential shift in the vaccine landscape, as Vaxcyte aims to challenge the dominance of established manufacturers like Pfizer and Merck. Providing coverage against more serotypes could offer more comprehensive protection for older populations.
The study enrolled 3,500 adults aged 50 and older who were randomized to receive either VAX-31, Pfizer's Prevnar, or Merck's Capvaxive. VAX-31 demonstrated coverage against 31 bacterial strains, compared to 20 for Prevnar and 21 for Capvaxive.
The players
Vaxcyte
This California-based biotechnology company focuses on developing vaccines designed to prevent infectious diseases.
Pfizer
This multinational pharmaceutical corporation manufactures Prevnar, a widely used vaccine protecting against 20 pneumococcal serotypes.
Merck
This major pharmaceutical company produces Capvaxive, a vaccine that targets 21 specific bacterial serotypes.
The details
Investigators measured the strength of antibody responses against various bacterial strains to verify the efficacy of the vaccine candidate. The results position the company to compete directly against existing pneumococcal vaccine offerings from industry giants.
Timeline
October 5, 2026: Vaxcyte reported the results of the Phase 3 clinical trial.
The Big Picture
This development represents a new entry into the pneumococcal vaccine market. It establishes a new benchmark for strain coverage that exceeds the thresholds currently maintained by industry leaders.
If approved, this vaccine could offer older adults broader protection against bacterial infections compared to currently available options. Patients should consult their healthcare providers regarding future immunization choices as new products enter the market.
The takeaway
Vaxcyte's recent clinical success highlights the trend toward increasing the number of bacterial strains covered by a single dose. Consumers should remain aware of ongoing vaccine research as manufacturers continue to compete for efficacy and coverage superiority.
Further reading
For more information on vaccine development and public health, visit our COVID-19 section.
Source note: This article includes information reported by STAT.
Live Poll
Do you believe newer medical vaccines are generally more effective than the options currently available?
